North Chicago, Illinois-based AbbVie Inc. (ABBV) is a research-based biopharmaceutical company that engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. Valued at a market cap of $386.3 billion, the company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta to treat blood cancers, among others.
Companies with a market capitalization of $200 billion or more are typically referred to as "mega-cap stocks." ABBV fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the general drug manufacturers industry.